Navigation Links
Haemacure and Angiotech Enter License, Distribution and Supply Agreements for Haemacure's All-Human Fibrin Sealant and Thrombin Products


    Haemacure Completes US$2.5 Million Bridge Financing from Angiotech

MONTREAL, June 3 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a Montreal-based specialty bio-therapeutics company, announces that Haemacure and Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX:ANP) have today closed a senior secured bridge loan from Angiotech to Haemacure in a minimum amount of US$2.5 million. The loan was described in detail in Haemacure's press release of May 22, 2009. In addition, Haemacure and Angiotech have executed definitive agreements for a strategic collaboration which will provide Angiotech with certain license, distribution and supply rights related to Haemacure's all-human fibrin sealant and thrombin products, both of which are currently in development.

"We believe this bridge financing and strategic collaboration with Angiotech provides an important validation of our company and its products. This will also position us for a larger, subsequent capital raise in order to complete the development and launch of our fibrin sealant and thrombin products on the market", said Joseph Galli, Chairman and Chief Executive Officer of Haemacure. "By collaborating with Angiotech, a company with a successful track record of innovation in drug delivery, we are expanding the number of product candidates that can be developed and leveraging our technology in new markets with significant unmet needs" concluded Mr. Galli.

    The strategic collaboration consists of the following three agreements:

    - Fibrin Sealant Distribution Agreement. Haemacure and Angiotech have
      entered into a distribution agreement under which Angiotech has been
      granted non-exclusive, world-wide distribution rights to Haemacure's
      hemostasis formulation of its proprietary fibrin sealant product in
      selected surgical indications. The distribution agreement has a term of
      ten years from the date on which Haemacure receives approval for its
      fibrin sealant from the United States Food and Drug Administration
      (FDA) or similar regulatory approval in other countries. Angiotech has
      an option to renew the agreement for an additional five years, subject
      to certain performance adjustments.
    - Drug-Loaded Fibrin Sealant License and Development Agreement. Haemacure
      and Angiotech have entered into a license and development agreement
      under which they have agreed to jointly develop and commercialize a
      next-generation, drug-loaded fibrin sealant product candidate.
      Angiotech and Haemacure will collaborate to create novel fibrin sealant
      technologies that, in addition to fibrin sealant's inherent hemostatic
      properties, may target the prevention of infection, reduce pain, or
      deliver stem cells using Haemacure's fibrin sealant as a carrier of
      such therapies. Haemacure and Angiotech will conduct research, with
      each contributing key personnel, technology and intellectual property.
      Collaboration costs and eventual profits will be shared on a pro rata
      basis, based on each company's contribution to collaboration costs.
      This term of the agreement will expire on a collaboration product-by-
      collaboration product basis upon the later of 15 years after the first
      commercial sale of such collaboration product, and the last-to-expire
      valid patent claim applicable to such collaboration product.
    - Thrombin License and Supply Agreement. Haemacure and Angiotech have
      entered into an exclusive license and supply agreement under which
      Haemacure will supply its proprietary human thrombin to Angiotech for
      the development of a certain Angiotech preclinical product candidate.
      The agreement has a term of ten years from the first commercial sale of
      an approved Angiotech product containing thrombin procured from
      Haemacure. Angiotech has an option to renew the agreement for an
      additional five years.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical haemostats. Haemacure's proprietary, lead product candidate is a fibrin sealant in late-stage clinical trials. Haemacure's proprietary, second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on the use of fibrin sealant in aesthetics, adhesion prevention, combination with biomaterials, drug delivery, regenerative medecine, skin graft fixation for burn injuries, and wound healing.

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit its website at

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Haemacure Update on Proposed Collaboration and Bridge Financing
2. Haemacure Signs Term Sheet for Proposed Collaboration and Bridge Financing
3. Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company
4. Haemacure Restructures - Seeks Financing or Sale of the Company
5. Haemacure to Present at the 11th Annual BIO CEO & Investor Conference
6. Haemacure Announces Fiscal 2008 Results
7. Haemacures Human Fibrin Sealant Demonstrates Effectiveness in Skin Graft Fixation Proof-of-Concept Study for Burn Injury
8. Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Payment from CSL
9. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
10. Haemacure Appoints Thomas J. Lynch, J.D., Ph.D. to Board of Directors
11. Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model
Post Your Comments:
(Date:10/10/2015)... ... ... have to walk with crutches for the rest of my life," said an inventor from ... that would give me more independence and freedom would be amazing. This inspired me to ... developed the STRAP IN to enable an individual to walk with crutches without having to ...
(Date:10/10/2015)... ... , ... Isabel Healthcare will participate in the Cerner Health Conference October 11-14, ... the Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel Healthcare will be ... providers and consumers to potentially reduce the chance of error. The report suggests that ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... highly sought after internships at the pre-eminent organization in global health: the World ... eliminating social and health disparities. These internships are a mechanism for WHO to ...
(Date:10/9/2015)... LINCOLN, R.I. (PRWEB) , ... October 09, 2015 , ... ... (NFPA), working smoke alarms can cut the risk of dying in reported home fires ... safety tips to make sure smoke alarms are property installed and maintained. , Half ...
(Date:10/9/2015)... ... 09, 2015 , ... On Saturday, September 26, 2015, 48-year-old MS survivor and ... Spain. Representing both the USA and Sweden in the Speed and Power events, which ... Crosses, she was awarded 1 Silver and 4 Gold Medals. , “I remember looking ...
Breaking Medicine News(10 mins):
... Kensey Nash Corporation (Nasdaq: KNSY ) ... New York Emerging Growth Institutional Investor Forum at The ... 24, 2009.Joseph W. Kaufmann, Kensey Nash,s CEO, will deliver ... The presentation materials will be available on the ...
... PT. RICHMOND, Calif., March 13 Transcept Pharmaceuticals, Inc. ... focused on the development and commercialization of proprietary products ... neuroscience, today announced it will report results for its ... market close. A conference call to review the results ...
... The American Parkinson Disease Association (APDA) and the National ... of Young Onset Parkinson Conferences; First to be held ... 13 The American Parkinson Disease Association,s ... Foundation,s (NPF) Young Onset Parkinson Network announced their first ...
... Finding suggests children with language disorders may benefit from ... Musical training enhances the ability to recognize emotion in ... musical training might benefit people with language problems and ... emotion in sound is a skill that translates across ...
... smartest decision, report says , , FRIDAY, March 13 (HealthDay ... drug plans available through Medicare don,t select the plan ... The report found that the more than 50 standalone ... the best value for their individual medical and financial ...
... Street has earned the number one spot in the ... of Outsourcing Customer Satisfaction Survey, 2008.Andrew DeVoe, CEO and ... recognition from the Health Insurance Industry and all our ... to excellence.""The fact that we have been ranked in ...
Cached Medicine News:
(Date:10/8/2015)... and PITTSBURGH , Oct. 8, 2015 ... global pharmaceutical company, will host a conference call and ... pm ET to review the value to be created ... ; TASE) through Mylan,s offer to acquire the company. ... which outlines the compelling proposition for Perrigo shareholders. Mylan,s ...
(Date:10/8/2015)... -- Following months of investigation, Ross Feller Casey , LLP ... the anticoagulant Xarelto,s recommended dosage doesn,t work for as long ... on behalf of a Florida ... didn,t work as the manufacturer suggested. Ross Feller Casey ... behalf of clients from across the country with similar claims. ...
(Date:10/8/2015)... CHARLOTTE, N.C. , Oct. 8, 2015  Clariant, a ... Healthcare Packaging manufacturing facility in Belen, New ... manufactured for healthcare applications, including desiccant canisters and packets ... Belen plant is the second Clariant site ... – to meet the ISO 15378:2011 standards, following only ...
Breaking Medicine Technology:
... 2012 announces that a new market ... Vaccines - Top 10 Global ... This market research report package offers an in-depth ... future outlook for vaccines in top 10 global ...
... HAIKOU, China, March 15, 2012 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... the "Company"), a fully-integrated specialty pharmaceuticals company in China, today ... Full Year Highlights , ... from $74.4 million in fiscal year 2010. , Income ...
Cached Medicine Technology:
Symbia T6, a True Point SPECT·CT system, combines a dual-detector variable angle gamma camera with a six slice CT scanner for advanced oncology, neurology, and cardiology applications....
... ACOM.PC turns every standard PC into ... internists, and cardiologists can use their ... access to image data thanks to ... 3 format and the compatible storage ...
... Soarian Cardiovascular Enterprise is a comprehensive ... care continuum from admission to follow-up. ... image acquisition, and diagnostic tools from ... provide a single, longitudinal clinical repository ...
... accurate lesion assessment plays a ... the appropriate stent size and ... (IC3D), a highly precise three-dimensional ... now able to quickly quantify ...
Medicine Products: